Inlyta (axitinib) — Medica
Thymic Carcinoma
Initial criteria
- Patient is age ≥ 18 years
- Patient has tried at least one chemotherapy regimen
- The medication will be used in combination with Bavencio (avelumab intravenous infusion)
Approval duration
1 year